Manitol Braun

Mannitol, the active ingredient in Manitol Braun, is an osmotic diuretic presented as an intravenous solution for intravenous use. It reduces intracranial and intra‑ocular pressure and promotes diuresis in conditions such as cerebral edema, acute renal failure, and glaucoma.

GNH USA supplies Manitol Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The product conforms to EU pharmacopeial standards and is manufactured under strict quality controls. It is available for bulk procurement and can be shipped under appropriate temperature conditions.

Manitol Braun, an osmotic diuretic, is employed in clinical situations that require rapid reduction of fluid volume in specific compartments. - Cerebral edema: reduces brain swelling and lowers intracranial pressure. - Increased intracranial pressure: rapidly decreases pressure to prevent neurological deterioration. - Acute renal failure: promotes osmotic diuresis to improve urine output. - Glaucoma: lowers intra‑ocular pressure by drawing fluid from the eye.

Mannitol may be associated with a range of adverse reactions, varying from mild to severe. Common Side Effects: - Headache: mild to moderate pain during infusion. - Nausea: feeling of queasiness that may lead to vomiting. - Thirst: increased desire for fluids. - Transient hypotension: temporary drop in blood pressure with rapid administration. Serious or Rare Side Effects: - Pulmonary edema: fluid accumulation in lungs requiring urgent care. - Severe dehydration: excessive fluid loss causing hypotension and organ dysfunction. - Acute renal failure: worsening kidney function in vulnerable patients. - Anaphylactic reaction: rare hypersensitivity needing immediate treatment.

When using Manitol Braun, clinicians should observe specific safety measures to minimize risks. - Monitor electrolytes: check serum sodium, potassium and osmolality regularly. - Assess renal function: evaluate creatinine clearance before and during therapy. - Use cautiously in heart failure: avoid rapid infusion in patients with compromised cardiac output. - Adjust infusion rate in hypovolemia: give slower bolus to prevent sudden plasma shifts. - Avoid concurrent nephrotoxic drugs: limit use with aminoglycosides or contrast agents. - Store at ambient temperature: keep in original container, protect from moisture and light.

Mannitol can interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - Loop diuretics (e.g., furosemide): additive diuretic effect may cause severe electrolyte loss. - Nephrotoxic agents (e.g., aminoglycosides, contrast media): increased risk of renal injury. - Insulin: enhanced hypokalemia risk due to combined intracellular shift of potassium. - Lithium: mannitol may increase lithium clearance, reducing therapeutic levels. Moderate Interactions (Monitor Closely): - Antihypertensives (e.g., ACE inhibitors, ARBs): may potentiate blood pressure lowering. - NSAIDs: can blunt diuretic response and affect renal perfusion. - Anticonvulsants (e.g., phenytoin): altered plasma protein binding may occur.